Dividend compounder review
BEAM
Beam Therapeutics Inc · NASDAQ · US
Healthcare · Biotechnology
Score30.50/100
Confidence78.00/100
DecisionInsufficient Data
RatingAvoid
Quality breakdown
Dividend Reliability
0.0 / 25
Payment history, cuts, growth, and regularity.
Dividend Sustainability
10.0 / 20
Payout, free cash flow, dividend cover, and debt.
Business Quality
11.5 / 25
Scale, cash generation, growth, margins, and returns.
Valuation Discipline
3.0 / 15
Yield, P/E, and price stretch versus long-term trend.
Long-Term Trend
6.0 / 15
Trend line, long return history, and drawdown control.
Dividend and business context
Dividend Years0
Dividend Yield0.00%
Payout Ratio0.0%
Dividend Cut 5YNo
Net Income$-80.0M
Free Cash Flow$-360.0M
FCF Covers DividendUnknown
Debt / Equity0.22
P/E-
Revenue Growth 5Y466.3%
Net Margin-40.2%
ROE-5.8%
Price vs Trend4.7%
3Y Return-8.7%
5Y Return-69.1%
CurrencyUSD
Review flags
No usable dividend history found.
Free cash flow is negative.
Activity record
Free cash flow is negative.